Because Harte Hanks carries effectively no active analyst coverage — TipRanks lists zero covering analysts and no forward price target, while figures still circulating on aggregator sites reflect stale, pre-merger research — the standard "average analyst price target" method does not apply here. Instead, the most realistic and widely discussed price objective is the $5.00 per share merger consideration set out in the definitive agreement announced on August 14, 2026. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Under those terms, Star Equity agreed to acquire Harte Hanks at a value of $5.00 per share, or roughly $38.4 million in equity value, with stockholders able to elect up to 50% cash (capped near $19.2 million) and the balance in Star's 10% Series A Cumulative Perpetual Preferred Stock (STRRP) at 0.50 preferred shares per Harte Hanks share. This is a documented, verifiable transaction price rather than a sell-side forecast.
Harte Hanks, Inc. is a global customer experience and business process outsourcing company operating through its Revenue Solutions, Customer Care, and Fulfillment and Logistics segments. The stock has recently traded near $4.01, with a 52-week range of roughly $2.00 to $4.67. A move to $5.00 therefore requires an advance of approximately 25%, a substantial gap that exists largely because the market is discounting for the possibility that the merger does not close on current terms.
The path to $5.00 is unusual for a stock price target: it is less about operating fundamentals and more about merger arbitrage. If the transaction closes as agreed, holders would receive consideration structured around the $5.00 valuation. If it does not, the share price would likely revert toward standalone fundamentals, which have been challenged — revenue has declined and the company has reported losses.
The most meaningful level is the $5.00 merger price itself, which acts as a natural ceiling for the stock while the deal is pending — shares rarely trade meaningfully above an agreed cash-and-stock takeover price absent a competing bid. Below that, the recent 52-week high near $4.67 is a notable reference point, and the stock has generally held above the $3.90–$4.00 area in recent sessions. These levels matter less as classic support or resistance and more as a gauge of how the market is pricing deal-completion risk.
Unlike a conventional analyst price target, which usually reflects a roughly 12-month research horizon, the $5.00 objective here is tied to a specific event: the merger, which both companies have said they expect to close before the end of 2026. Investors should watch for the Harte Hanks special stockholder meeting and vote, the effectiveness of the Form S-4, any changes in financing or deal terms, and any competing or superior proposals that could emerge. The company's quarterly results, including the most recent third-quarter report, remain relevant mainly as a fallback measure of standalone value. I'm watching this closely as the timeline tightens.
The question of whether Harte Hanks can reach $5.00 is really a question about whether the pending Star Equity acquisition closes on its agreed terms. The $5.00 figure is a transaction price, not an analyst consensus, and it sits roughly 25% above the recent trading level — a substantial gap that reflects genuine completion risk rather than fundamental upside. The strongest supports are the board's recommendation and the failure of the go-shop process to surface a superior bid, while the principal obstacles are the outstanding stockholder vote, financing conditions, and the preferred-stock component of the consideration. Investors should monitor the special meeting, regulatory filings, and any changes to deal terms, while recognizing that if the merger were to fail, the stock would likely be reassessed on much weaker standalone fundamentals. No outcome is guaranteed.
In my own research process, I rely on Tickeron's AI Daily Buy/Sell Signals to help track momentum shifts in deals like this one. The tool uses artificial intelligence to monitor thousands of stocks and generate signals based on technical behavior and market conditions. It has been useful for spotting changes in sentiment when traditional coverage is limited, allowing me to stay informed on positions without constant manual review.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
HHS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 32 of 39 cases where HHS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 82%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where HHS's RSI Oscillator exited the oversold zone, 19 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 66%.
The Moving Average Convergence Divergence (MACD) for HHS just turned positive on November 09, 2026. Looking at past instances where HHS's MACD turned positive, the stock continued to rise in 41 of 52 cases over the following month. The odds of a continued upward trend are 79%.
Following a +2.58% 3-day Advance, the price is estimated to grow further. Considering data from situations where HHS advanced for three days, in 181 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 35 of 52 cases where HHS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 67%.
The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HHS as a result. In 74 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.
HHS moved below its 50-day moving average on October 20, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for HHS crossed bearishly below the 50-day moving average on October 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HHS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The Aroon Indicator for HHS entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.923) is normal, around the industry mean (-1.578). P/E Ratio (-5.143) is within average values for comparable stocks, (18.965). Projected Growth (PEG Ratio) (0.472) is also within normal values, averaging (0.772). Dividend Yield (0.859) settles around the average of (674.816) among similar stocks. P/S Ratio (0.219) is also within normal values, averaging (2.059).
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. HHS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HHS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of marketing and shopper advertising services
Industry IndustrialConglomerates